tetano
Editor, Senior Moderator
[h=2]Increased risk of influenza among vaccinated adults who are obese[/h] S D Neidich[SUP]1[/SUP], W D Green[SUP]2[/SUP], J Rebeles[SUP]2[/SUP], E A Karlsson[SUP]3[/SUP], S Schultz-Cherry[SUP]3[/SUP], T L Noah[SUP]4[/SUP], S Chakladar[SUP]5[/SUP], M G Hudgens[SUP]5[/SUP], S S Weir[SUP]6[/SUP] and M A Beck[SUP]2[/SUP]
Received 12 January 2017; Revised 16 March 2017; Accepted 16 April 2017
Accepted article preview online 6 June 2017
Top of page [h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Influenza infects 5?15% of the global population each year, and obesity has been shown to be an independent risk factor for increased influenza-related complications including hospitalization and death. However, the risk of developing influenza or ILI in a vaccinated obese adult population has not been addressed.
[h=4]OBJECTIVE:[/h] This study evaluated whether obesity was associated with increased risk of influenza and influenza-like illness among vaccinated adults.
[h=4]SUBJECTS AND METHODS:[/h] During the 2013?2014 and 2014?2015 influenza seasons, we recruited 1042 subjects to a prospective observational study of trivalent inactivated influenza vaccine (IIV3) in adults.1022 subjects completed the study. Assessments of relative risk for laboratory confirmed influenza and influenza-like illness were determined based on BMI. Seroconversion and seroprotection rates were determined using pre-vaccination and 26?35 days post-vaccination serum samples. Recruitment criteria for this study were adults 18 years of age and older receiving the seasonal trivalent inactivated influenza vaccine (IIV3) for the years 2013?2014 and 2014?2015. Exclusion criteria were immunosuppressive diseases, use of immunomodulatory or immunosuppressive drugs, acute febrile illness, history of Guillain-Barre syndrome, use of theophylline preparations, or use of warfarin.
[h=4]RESULTS:[/h] Among obese, 9.8% had either confirmed influenza or influenza-like-illness compared with 5.1% of healthy weight participants. Compared with vaccinated healthy weight, obese participants had double the risk of developing influenza or influenza-like illness (relative risk=2.01, 95% CI 1.12, 3.60, P=0.020). Seroconversion or seroprotection rates were not different between healthy weight and obese adults with influenza or ILI.
[h=4]CONCLUSIONS:[/h] Despite robust serological responses, vaccinated obese adults are twice as likely to develop influenza and influenza-like illness compared to healthy weight adults. This finding challenges the current standard for correlates of protection, suggesting use of antibody titers to determine vaccine effectiveness in an obese population may provide misleading information.
http://www.nature.com/ijo/journal/vaop/naam/abs/ijo2017131a.html
- [SUP]1[/SUP]Human Vaccine Institute, Duke University
- [SUP]2[/SUP]Department of Nutrition, University of North Carolina at Chapel Hill
- [SUP]3[/SUP]Department of Infectious Diseases, St Jude Children?s Research Hospital
- [SUP]4[/SUP]Department of Pediatrics, University of North Carolina at Chapel Hill
- [SUP]5[/SUP]Department of Biostatistics, University of North Carolina at Chapel Hill
- [SUP]6[/SUP]Department of Family Medicine, University of North Carolina at Chapel Hill
Received 12 January 2017; Revised 16 March 2017; Accepted 16 April 2017
Accepted article preview online 6 June 2017
Top of page [h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Influenza infects 5?15% of the global population each year, and obesity has been shown to be an independent risk factor for increased influenza-related complications including hospitalization and death. However, the risk of developing influenza or ILI in a vaccinated obese adult population has not been addressed.
[h=4]OBJECTIVE:[/h] This study evaluated whether obesity was associated with increased risk of influenza and influenza-like illness among vaccinated adults.
[h=4]SUBJECTS AND METHODS:[/h] During the 2013?2014 and 2014?2015 influenza seasons, we recruited 1042 subjects to a prospective observational study of trivalent inactivated influenza vaccine (IIV3) in adults.1022 subjects completed the study. Assessments of relative risk for laboratory confirmed influenza and influenza-like illness were determined based on BMI. Seroconversion and seroprotection rates were determined using pre-vaccination and 26?35 days post-vaccination serum samples. Recruitment criteria for this study were adults 18 years of age and older receiving the seasonal trivalent inactivated influenza vaccine (IIV3) for the years 2013?2014 and 2014?2015. Exclusion criteria were immunosuppressive diseases, use of immunomodulatory or immunosuppressive drugs, acute febrile illness, history of Guillain-Barre syndrome, use of theophylline preparations, or use of warfarin.
[h=4]RESULTS:[/h] Among obese, 9.8% had either confirmed influenza or influenza-like-illness compared with 5.1% of healthy weight participants. Compared with vaccinated healthy weight, obese participants had double the risk of developing influenza or influenza-like illness (relative risk=2.01, 95% CI 1.12, 3.60, P=0.020). Seroconversion or seroprotection rates were not different between healthy weight and obese adults with influenza or ILI.
[h=4]CONCLUSIONS:[/h] Despite robust serological responses, vaccinated obese adults are twice as likely to develop influenza and influenza-like illness compared to healthy weight adults. This finding challenges the current standard for correlates of protection, suggesting use of antibody titers to determine vaccine effectiveness in an obese population may provide misleading information.
http://www.nature.com/ijo/journal/vaop/naam/abs/ijo2017131a.html